ValiRx plc ( (GB:VAL) ) has issued an announcement.
ValiRx plc announced the successful passing of all resolutions at its General Meeting, leading to the issuance of 241,999,999 new ordinary shares and an equal number of Fundraise Warrants. This fundraising effort is expected to enhance the company’s financial position, potentially improving its operations and market presence.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines.
YTD Price Performance: -88.56%
Average Trading Volume: 1,918,959
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £893.4K
See more data about VAL stock on TipRanks’ Stock Analysis page.